Minims (Atropine Sulfate)

Atropine sulfate blocks muscarinic acetylcholine receptors in the iris sphincter and ciliary body. By preventing parasympathetic signaling, it stops pupil constriction and accommodation, leading to sustained dilation (mydriasis) and loss of focusing ability (cycloplegia) for several hours.

The prescribed dose of Minims is determined by the treating eye‑care professional. Typically, a single drop is instilled in the affected eye(s) as directed, and the frequency or repeat dosing is based on the specific diagnostic or procedural requirement.

The safety of atropine sulfate in pregnancy and lactation is not well established. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by the prescriber in consultation with the patient.

To order Minims, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and import documentation.

The primary alternative to atropine sulfate is tropicamide, which has a shorter duration of action and a lower risk of prolonged cycloplegia. Atropine provides a longer‑lasting dilation, useful for procedures that require extended pupil opening, but it may carry a higher incidence of systemic anticholinergic effects.

Store Minims at room temperature, preferably below 25 °C. Keep the vial in its original packaging, protect it from direct light and moisture, and ensure the cap is tightly closed to maintain sterility and potency.

Minims is applied topically to the eye. The prescriber typically instructs the patient to instill one drop into the conjunctival sac of the target eye(s) using a sterile technique, avoiding contact of the dropper tip with the ocular surface or any other surface.

Serious risks include acute angle‑closure glaucoma, which can cause a rapid increase in intraocular pressure, and systemic anticholinergic toxicity, presenting as dry mouth, rapid heart rate, confusion or delirium. Severe allergic reactions such as swelling, rash or anaphylaxis also require immediate medical attention.

Minims should be avoided in patients with known narrow‑angle or angle‑closure glaucoma, hypersensitivity to atropine or any formulation component, and in children unless specifically directed by an ophthalmologist. Caution is also advised for individuals taking other anticholinergic medications.